Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNCAR-001 + STK-009 in CD19+ Hematologic Malignancies
NCT05665062Phase 1Active, not recruiting
- Sponsor
- Synthekine
- Start
- Apr 2023
- Primary completion
- Jun 2028
- Modality
- CAR-T Cells, PEGylated Peptides, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of SYNCAR-001 and STK-009 in hematologic malignancy (2 cohorts), sponsored by Synthekine. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 24 months. Started Apr 2023; status: active, not recruiting.
02
Drugs
SYNCAR-001STK-009
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT05665062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05665062.